Targeting the COPD Exacerbation

Respiratory Medicine

Volumn 102, Issue SUPPL. 1, 2008, Pages

  Decramer, Marc ^a   Nici, Linda ^b   Nardini, Stefano ^c   Reardon, Jane ^d   Rochester, Carolyn L ^e   Sanguinetti, Claudio M ^f   Troosters, Thierry ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d HARTFORD HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

COPD; Exacerbation; Pharmacotherapy; Rehabilitation; Self management; Systematic consequences and prevention strategies

Indexed keywords

ACETYLCYSTEINE; BACTERIUM LYSATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IMMUNOFERON; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR; PNEUMOCOCCUS VACCINE; PREDNISONE; ROFLUMILAST; SALMETEROL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; HEALTH CARE UTILIZATION; HUMAN; IMMUNIZATION; INFLAMMATION; LUNG CIRCULATION; LUNG FUNCTION; OXYGEN THERAPY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULMONARY REHABILITATION; RELAPSE; RISK FACTOR; SKELETAL MUSCLE; SMOKING CESSATION; SOCIAL SUPPORT; SURVIVAL; SYSTEMIC CIRCULATION; TREATMENT INDICATION;

ACTIVITIES OF DAILY LIVING; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; OXYGEN INHALATION THERAPY; PATIENT ACCEPTANCE OF HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; SMOKING CESSATION;

EID: 45849097984     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(08)70003-9     Document Type: Article

References (95)

1. Seemungal T., Donaldson G., Paul E., Bestall J., Jeffries D., and Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1418-1422
2. Domingo-Salvany A., Lamarca R., Ferrer M., et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 680-685
3. Rabe K., Hurd S., Anzueto A., Barnes P., Buist S., Calver-ley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 176 (2007) 532-555
4. American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD (2004). http://www.thoracic.org/copd
5. NICE Guideline No. 12. Chronic obstructive pulmonary disease. Thorax 59 Suppl 1 (2004) 131
6. Wedzicha J., and Hurst J. Chronic obstructive pulmonary disease exacerbation and risk of pulmonary embolism. Thorax 62 (2007) 103-104
7. Garcia-Aymerich J., Monso E., Marrades R., et al., for the EFRAM Investigators. Risk factors for hospitalization for a COPD exacerbation: the EFRAM study. Am J Respir Crit Care Med 164 (2001) 1002-1007
8. Donaldson G., Seemungal T., Bhowmik A., and Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
9. Garcia-Aymerich J., Farrero E., Felez M., et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58 (2003) 100-105
10. Spruit M., Gosselink R., Troosters T., et al. Muscle force during an acute exacerbation in hospitalized patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 59 9 (2003) 741-742
11. Andersson F., Borg S., Jansson S., et al. The costs of exacerbations in chronic obstructive pulmonary disease. Respir Med 96 (2002) 700-708
12. Price M., and Hurrell C. Health care costs of treating exacerbations of COPD. Eur Respir J (1999) 14
13. Connors Jr. A., Dawson N., Thomas C., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 154 4 pt 1 (1996) 959-967
14. Wilkinson T., Donaldson G., Hurst J., Seemungal T., and Wedzicha J. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 169 (2004) 1298-1303
15. Bourbeau J., Julien M., Maltais F., et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Sante du Quebec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease. Arch Int Med 163 5 (2003) 585-591
16. Saetta M., Di Stefano A., Maestrelli P., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150 (1994) 1646-1652
17. Zhu J., Qiu Y., Majumdar S., et al. Exacerbations of bron-chitis. Bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattrac-tant. Am Rev Respir Crit Care Med 164 (2001) 109-116
18. Tsoumakidou M., Tzanakis N., Chrysofakis G., et al. Changes in sputum T-lymphocyte subpopulation at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 99 (2005) 572-579
19. Fiorini G., Crespi S., Rinaldi M., et al. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 54 (2000) 274-278
20. Hurst J., Wilkinson T., Perera W., et al. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 127 (2005) 1219-1226
21. Hurst J., Perera W., Wilkinson T., et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am Rev Respir Crit Care Med 173 (2006) 71-78
22. Roland M., Bhowmik A., Sapsford R., et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 56 (2001) 30-35
23. Hurst J., Donaldson G., Perera W., et al. Utility of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 174 (2006) 867-874 Epub 2006 Jun 23.
24. Wilkinson T., Powrie D., Perera W., et al. Relationship between stable state inflammation and time to exacerbation in patients with COPD. Eur Respir J 28 suppl.50 (2006) 177s
25. Perera W., Hurst J., Wilkinson T., and Donaldson G. Serum C-reactive protein 14 days after a COPD exacerbation and time to the next exacerbation. Eur Respir J 28 suppl.50 (2006) 177s
26. Creutzberg E., Wouters E., vanderHoven-Augustin I., et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162 (2000) 1239-1245
27. Vermeeren M., Schols A., and Wouters E. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J 10 (1997) 2264-2269
28. Buist A., Sexton G., Nagy J., and Ross B. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 114 (1976) 115-122
29. Patel I., Seemungal T., Wilks M., Lloyd-Owen S., Donaldson G., and Wedzicha J. Relationship between bacterial colonization and the frequency, character and severity of COPD exacerbations. Thorax 57 (2002) 759-764
30. Anthonisen N., Skeans M., Wise R., Manfreda J., Kan-ner R., Connett J., and Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
31. Nichol K., Baken L., and Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly patients with chronic lung disease. Ann Intern Med 130 (1999) 397-403
32. Howells C., and Tyler L. Prophylatic use of influenza vaccine in patients with chronic bronchitis. Lancet 2 (1961) 1428-1432
33. Nichol K., Baken L., Wuorenma J., and Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly patients with chronic lung disease. Arch Intern Med 159 (1999) 2437-2442
34. Ringbaek T., Viskum K., and Lange P. Does long-term oxygen therapy reduce hospitalization in hypoxemic COPD?. Eur Respir J 20 (2002) 38-42
35. Goldstein RS. Perspectives that influence action plans in COPD. Abstract presented at ATS International Conference in San Diego, 2006.
36. Monninkhof E., van der Aa M., van der Valk P., et al. A qualitative evaluation of a comprehensive self-management programme for COPD patients: effectiveness from the patients' perspective. Patient Education & Counseling 55 2 (2004) 177-184
37. Gadoury M., Schwartzman K., Rouleau M., et al. Self-management reduces both short- and long-term hospitali-sation in COPD. Eur Respir J 26 5 (2005) 853-857
38. Bourbeau J., Collet J., Schwartzman K., Ducruet T., Nault D., and Bradley. Economic benefits of self-management education in COPD. Chest 130 (2006) 1704-1711
39. Farrero E., Escarrabill J., Prats E., et al. Impact of a hospital-based home care program on the management of COPD patients receiving long-term oxygen therapy. Chest 119 (2001) 364-369
40. Hernandez C. Enhanced integrated care management of COPD patients using a wireless point-of-care application. Abstract presented at the ATS International Conference in San Diego, 2006.
41. Nici L., Donner C., Wouters E., ZuWallack R., et al. ATS and ERS statement on pulmonary Rehabilitation. Am J Respir Crit Care Med 15 173 (2006) 1390-1413
42. Scherer Y., Schmieder L., and Shimmel S. The effects of education alone and in combination with pulmonary rehabilitation on self-efficacy in patients with COPD. Rehabil Nurs 23 2 (1998) 71-77
43. Puhan M., Scharplatz M., Troosters T., et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality - a systematic review. Respir Res 6 1 (2005) 54
44. Man W., Polkey M., Donaldson N., et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 329 7476 (2004) 1209
45. Rutten F., Cramer M., Grobbee D., et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 18 (2005) 1887-1894
46. Rutten F., Cramer M., Lammers J., et al. Heart failure and chronic obstructive pulmonary disease: An ignored combination?. Eur J Heart Fail (2006)
47. Ambrosetti M., Ageno W., Spanevello A., et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 112 4 (2003) 203-207
48. Kessler R., Faller M., Fourgaut G., et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 1 (1999) 158-164
49. Stevenson N., Walker P., Costello R., et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 12 (2005) 1510-1516
50. Troosters T, Pitta F, Gayan-Ramirez G et al. Acute exacerbations reduce Hemoglobin concentrations in patients with COPD. A link with systemic inflammation and oxida-tive stress. submitted 2006.
51. Pepin V., Saey D., Whittom F., LeBlanc P., and Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 1517-1522
52. Probst V., Troosters T., Pitta F., et al. Cardiopulmonary stress during exercise training in patients with COPD. Eur Respir J 27 6 (2006) 1110-1118
53. Vivodtzev I., Pepin J., Vottero G., et al. Improvement in quadriceps strength and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. Chest 129 6 (2006) 1540-1548
54. Neder J., Sword D., Ward S., et al. Home based neu-romuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax 57 4 (2002) 333-337
55. Yohannes A., and Connolly M. Early mobilization with walking aids following hospital admission with acute exacerbation of chronic obstructive pulmonary disease. Clin Rehabil 17 5 (2003) 465-471
56. Probst V., Troosters T., Coosemans I., et al. Mechanisms of improvement in exercise capacity using a rollator in COPD. Chest 126 4 (2004) 1102-1107
57. Kirsten D., Taube C., Lehnigk B., et al. Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med 92 10 (1998) 1191-1198
58. Murphy N., Bell C., and Costello R. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir Med 99 10 (2005) 1297-1302
59. Pitta F., Troosters T., Probst V., et al. Physical activity and hospitalization for exacerbation of COPD. Chest 129 3 (2006) 536-544
60. Probst V, Troosters T, Celis G et al. Effect of resistance training during hospitalization due to acute exacerbations of COPD; preliminary results. 2005: 432s.
61. Casas A., Troosters T., Garcia-Aymerich J., et al. Integrated care prevents hospitalizations for exacerbations in COPD patients. Eur Respir J (2006)
62. Friedman M., Serby C., Menjoge S., Wilson J., Hilleman D., and Witek T. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipra-tropium alone and albuterol alone in COPD. Chest 115 (1999) 635-641
63. Appleton S., Poole P., Smith B., Veale A., Lasserson T., and Chan M. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease (Review). Cochr Database Syst Rev 3 (2006) 1-84
64. Ferguson G., Funck-Brentano C., Fischer T., Darken P., and Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 123 6 (2003) 1817-1824
65. Casaburi R., Mahler D., Jones P., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
66. Vincken W., van Noord J., Greefhorst A., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
67. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
68. Niewoehner D., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bron-chodilator. Ann Intern Med 143 (2005) 317-326
69. Barr R., Bourbeau J., Camargo C., and Ram F. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (2005) 10.1002/14651858.CD002876.pub2 Issue 2. Art. No.: CD002876.
70. Aaron S., Vandemheen K., Hebert P., et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. New Engl J Med 348 (2003) 2618-2625
71. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., and Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
72. Bourbeau J., Rouleau M., and Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 53 (1998) 477-482
73. Burge P., Calverley P., Jones P., et al. Randomised, double blind, placebo controlled study of fluticasone pro-pionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
74. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 343 (2000) 1902-1909
75. Alsaeedi A., Sin D., and McAlister F. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized, placebo-controlled trials. Am J Med 113 (2002) 59-65
76. Van der Valk P., Monninkhof E., van der Palen J., Zielhuid G., and vsn Herwaarden C. Effect of discontinuation of inhaled cor-ticosteroids in patients with chronic obstructive pulmonary disease: The COPE Study. Am J Respir Crit Care Med 166 (2002) 1358-1363
77. Wouters E., Postma D., Fokkens B., et al. Withdrawal of fluticasone propionate from combined salme-terol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60 (2005) 480-487
78. Sin D., and Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 580-587
79. Calverley P., Pauwels R., Vestbo J., et al. Combined salme-terol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
80. Calverley P., Anderson J., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 356 8 (2007) 775-789
81. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
82. Calverley P. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
83. Aaron S., Vandemheen K., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease, a randomized trial. Ann Intern Med 146 (2007) 545-555
84. Rabe K., Bateman E., O'Donnell D., Witte S., Bredenbro-ker K., and Bethke T. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366 (2005) 563-571
85. Rennard S., Schacter N., Strek M., Rickard K., and Amit O. Cilomi-last for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase-4. Chest 129 (2006) 56-66
86. Gerrits C., Herings R., Leufkens H., and Lammers J. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 795-798
87. Pela R., Calcagni A., Subiaco S., Isidori P., Tubaldi A., and San-guinetti C. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66 (1999) 495-500
88. Stey C., Steurer J., Bachmann S., Medici T., and Tramer M. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16 (2000) 253-262
89. Poole P., and Black P. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2 5 (2003) 367-370
90. Decramer M., Rutten-van Molken M., Dekhuijzen P., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC cost-utility study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
91. Collett J., Shapiro S., Ernst P., Renzi P., Ducruet T., and Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156 (1997) 1719-1724
92. Prieto A., Reyes E., Bernstein E., et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopep-tical (Inmunoferon). Am J Respir Crit Care Med 163 (2001) 1578-1583
93. Alvarez-Mon M., Miravitlles M., Morera J., Callol L., and Alvarez-Sala J. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest 127 (2005) 1212-1218
94. Casaburi R., Kukafka D., Cooper C., Witek Jr. T., and Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127 (2005) 809-817
95. Koechlin C., Couillard A., Simar D., Cristol J., Bellet H., Hayot M., and Prefaut C. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 169 (2004) 1022-1027